Aurobindo Pharma Limited — Board Meeting, 09-11-2024: Outcome of Board Meeting

The Board of Directors of Aurobindo Pharma Limited convened on November 9, 2024, and approved the unaudited standalone and consolidated financial results for the second quarter and half-year ending September 30, 2024. Key figures include a standalone revenue from operations of ₹51,831.0 Cr, resulting in a profit before tax of ₹11,699.9 Cr, marking an increase compared to previous periods. The board also confirmed that the amalgamation of Mviyes Pharma Ventures and Auronext Pharma has been effective since May 17, 2024. Notably, the company reported significant investments in subsidiaries abroad and a buyback of equity shares, totaling ₹9,302.4 Cr. All reported financials reflect a robust operational trajectory amidst ongoing strategic initiatives.